LabCorp and Envigo Complete Innovative Transactions Read more about LabCorp and Envigo Complete Innovative Transactions
LabCorp Announces Availability of New QIAGEN therascreen FGFR mutation analysis companion diagnostic for Bladder Cancer Read more about LabCorp Announces Availability of New QIAGEN therascreen FGFR mutation analysis companion diagnostic for Bladder Cancer
Mark S. Schroeder Mark S. Schroeder EVP and President, Diagnostics Laboratories and Chief Operations Officer Mark Schroeder has served as Labcorp’s Executive Vice President and President, Diagnostics and Chief Operations Officer since 2023. In this role, Mark leads all Diagnostics divisions and commercial teams, as well as routine and esoteric testing laboratory operations for Labcorp Diagnostics and global supply chain. Since joining Labcorp in 2007, Mark has held numerous senior leadership positions in laboratory and supply chain operations. Previously, he led Labcorp’s West Division as well as its Integrated Genetics, Integrated Oncology and Dianon Pathology businesses. Mark was instrumental in developing and expanding the company’s laboratory capabilities in response to the COVID-19 pandemic and has been an integral architect of process improvement initiatives for Labcorp and of the company’s growth in diagnostics. Before joining Labcorp, Mark served as the Senior Vice President of Sales, Operations and Business Development at DSC Logistics. Mark serves on the FedEx Healthcare Industry Advisory Board as well as the Flare Capital Partners Advisory Board. He earned a Bachelor of Science in interdisciplinary engineering and management from Clarkson University.
LabCorp to Webcast Its Annual Meeting of Shareholders Read more about LabCorp to Webcast Its Annual Meeting of Shareholders
LabCorp Announces 2019 First Quarter Results and Increases 2019 Earnings Guidance Read more about LabCorp Announces 2019 First Quarter Results and Increases 2019 Earnings Guidance
LabCorp and Envigo Sign Innovative Agreement to Expand Covance’s Nonclinical Drug Development Capabilities and Create an Independent Research Models Provider Read more about LabCorp and Envigo Sign Innovative Agreement to Expand Covance’s Nonclinical Drug Development Capabilities and Create an Independent Research Models Provider
LabCorp to Announce First Quarter Financial Results on April 30, 2019 Read more about LabCorp to Announce First Quarter Financial Results on April 30, 2019
Conversion Right Triggered for LabCorp’s Zero Coupon Convertible Subordinated Notes Due 2021 Read more about Conversion Right Triggered for LabCorp’s Zero Coupon Convertible Subordinated Notes Due 2021
LabCorp Earns 100 Percent on Human Rights Campaign Foundation’s 17th Annual Scorecard on LGBTQ Workplace Equality Read more about LabCorp Earns 100 Percent on Human Rights Campaign Foundation’s 17th Annual Scorecard on LGBTQ Workplace Equality
LabCorp’s Zero Coupon Convertible Subordinated Notes Due 2021 to Accrue Contingent Interest Read more about LabCorp’s Zero Coupon Convertible Subordinated Notes Due 2021 to Accrue Contingent Interest